Clinical Trials Logo

Clinical Trial Summary

The aim of this research is to collect dietary intake, physical activity, mood and stress data during and after the Illinois shelter-in-place and social distancing orders for the COVID-19 pandemic. The study's intent is to capture data during this unprecedented time to understand the non-infection consequences of social distancing and shelter-in-place, including duration of affect after orders are lifted.


Clinical Trial Description

The proposed study is an observational study. The study will include our previous subjects, those who are following the shelter- in- place order due to the COVID-19 pandemic. Demographic data of individuals participating in the study will be recorded. During this 12-month protocol, participants will be contacted through email to complete online questionnaires on weekly basis for 8 weeks, and then once every 4 weeks until the end of the study. Subjects will record their one-day food intake, physical activity, sleep, and stress and anxiety level, which takes ~1 hour to complete. Subjects will be recruited through our CNRC databases of individuals who come to our clinic in the past 1 year, online advertisement, and word of mouth. A phone and/or email will be administered to ensure their eligibility using our standard tools and protocols. People who are willing and able to participate and meet the basic screening eligibility will be contacted through email for informed consent and the continuing of the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04357041
Study type Observational
Source Clinical Nutrition Research Center, Illinois Institute of Technology
Contact
Status Completed
Phase
Start date April 17, 2020
Completion date July 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04722848 - Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL Phase 3
Recruiting NCT05024357 - A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL N/A
Recruiting NCT05026229 - A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL N/A
Recruiting NCT06052813 - A Study of BN104 in the Treatment of Acute Leukemia Phase 1/Phase 2
Completed NCT05928104 - Optimising Pharmacist-led Medication Reviews in Primary Care
Recruiting NCT05473910 - A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation Phase 1
Recruiting NCT03884829 - A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Phase 1
Active, not recruiting NCT03541083 - Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. Phase 2
Recruiting NCT06250959 - RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL. Phase 2
Active, not recruiting NCT03751709 - Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL Phase 1
Recruiting NCT04482894 - Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Phase 2
Recruiting NCT05480904 - Characterizing Sleep Among Long-term Survivors of Childhood Cancer